Lymphoma Clinical Trials in Philadelphia

Showing 301-317 of 317 trials

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

NCT00886496

RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer. PURPOSE: This phase I trial is studying the side effects and best dose of recombinant human mannose-binding lectin in treating young patients with MBL deficiency and fever and neutropenia.

Fever, Sweats, and Hot FlashesInfectionLeukemia+4 more

Enzon Pharmaceuticals, Inc.Started Nov 2006

Orange, California, United States • Washington D.C., District of Columbia, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPHASE2< 1 mile

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

NCT00501735

This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia. This study is designed to assess objective response (OR) \[complete response (CR) or partial response (PR)\] in subjects with cutaneous manifestations of CTCL with a requirement for maintenance of such objective response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally, this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB, III, or IVA treated with oral forodesine.

Cutaneous T-cell Lymphoma (CTCL),

BioCryst Pharmaceuticals144 participantsStarted Jul 2007

Birmingham, Alabama, United States • Stanford, California, United States • New Haven, Connecticut, United States +38 more locations

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Lymphoma Trials in Other Cities

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in Philadelphia